

Reckitt Benckiser Investor Presentation: Half Year 2014

28th July 2014

1



Rakesh Kapoor Chief Executive Officer

Key messages



Continued focus on the core

Virtuous Earnings model delivering

On track for full year delivery

Continued focus on the core



Organic

Health led Growth

Ytd LFL growth of **+10%**

Building capabilities for the future

M&A

BMS

Fully integrated – net revenue **well above market growth**

KY

US, and Canada already integrated


Divestitures

Scholl Footwear

Agreement signed for disposal of the business

Virtuous earnings model delivering






Virtuous earning model - ENA Part II



Part I - Delayering




Part II - Brand / Customer mgt



ENA brand management







ENA brand management







HY 2014: On Track



Health led revenue growth:

HY 2014 net revenue +4% LFL (ex-RBP)

Increased investment behind brands – BEI up by £10m*, -30bps vs PY

Good Margin expansion

Gross margin **+60bps** driven by mix and cost savings programmes

Operating margin +40bps funded by GM and efficiencies

Strong cash conversion 90% of net revenue

Interim dividend maintained at 60p

* constant, ex RBP



Adrian Hennah Chief Financial Officer

HY 2014 results Income statement



	Q2		H	1
	2014	2013	2014	2013
	£m	£m	£m	£m
Revenue	2,299	2,477	4,667	4,994
LFL %	3%	4%	3%	5%
Revenue excl RBP	2,125	2,278	4,323	4,594
LFL% excl RBP	4%	6%	4%	6%
Gross Margin			2,767	2,929
Gross Margin %			59.3%	58.7%
Adjusted Operating Profit*			1,081	1,163
Adjusted Operating Profit %			23.2%	23.3%
AOP excl RBP*			898	935
AOP% margin excl RBP			20.8%	20.4%
Exceptionals			(22)	(249)
Operating Profit			1,059	914

HY 2014 results Income statement



	H	1
	2014	2013
	£m	£m
Operating profit	1,059	914
Net pension finance expense	(4)	(6)
Other net finance expense	(14)	(10)
Profit before taxation	1,041	898
Taxation	(229)	(237)
Tax rate excluding exceptionals	22%	25%
Tax rate including exceptionals	22%	26%
Non-controlling Interest	-	(1)
Net Income	812	660
Adjusted Net Income*	829	864
Diluted EPS	111.1p	90.4p
Adjusted diluted EPS	113.4p	118.3p

Revenue growth by Quarter Business Segment



	2013			2014		
Q1	Q2	Q3	Q4	Q1	Q2	HY
LFL	LFL	LFL	LFL	LFL	LFL	LFL
3%	3%	2%	2%	2%	2%	2%
11%	11%	10%	9%	8%	6%	7%
7%	5%	5%	3%	4%	7%	5%
3%	-2%	1%	0%	3%	2%	3%
6%	6%	5%	4%	4%	4%	4%
19%	-12%	-16%	-18%	-11%	-5%	-8%
7%	4%	3%	2%	2%	3%	3%
	11% 7% 3% 6% 19%	Q1 Q2 LFL LFL 3% 3% 11% 11% 7% 5% 3% -2% 6% 6% 19% -12%	Q1 Q2 Q3 LFL LFL LFL 3% 3% 2% 11% 11% 10% 7% 5% 5% 3% -2% 1% 6% 6% 5% 19% -12% -16%	Q1 Q2 Q3 Q4 LFL LFL LFL LFL 3% 3% 2% 2% 11% 11% 10% 9% 7% 5% 5% 3% 3% -2% 1% 0% 6% 6% 5% 4% 19% -12% -16% -18%	Q1 Q2 Q3 Q4 Q1 LFL LFL LFL LFL 3% 3% 2% 2% 2% 11% 11% 10% 9% 8% 7% 5% 5% 3% 4% 3% -2% 1% 0% 3% 6% 6% 5% 4% 4% 19% -12% -16% -18% -11%	Q1 Q2 Q3 Q4 Q1 Q2 LFL LFL LFL LFL LFL 3% 3% 2% 2% 2% 11% 11% 10% 9% 8% 6% 7% 5% 5% 3% 4% 7% 3% -2% 1% 0% 3% 2% 6% 6% 5% 4% 4% 4% 19% -12% -16% -18% -11% -5%

Revenue growth by Quarter Category



		2013			2014		
	Q1	Q2	Q3	Q4	Q1	Q2	HY
	LFL	LFL	LFL	LFL	LFL	LFL	LFL
Health	13%	16%	8%	7%	11%	10%	10%
Hygiene	9%	5%	7%	6%	2%	4%	3%
Home	2%	3%	0%	3%	1%	-1%	0%
Portfolio	-22%	-5%	-5%	-16%	-3%	-8%	-6%
Food	3%	-2%	1%	0%	3%	2%	3%
Group excluding RBP	6%	6%	5%	4%	4%	4%	4%
RBP	19%	-12%	-16%	-18%	-11%	-5%	-8%
Group	7%	4%	3%	2%	2%	3%	3%

Margin Analysis



В	ase	F	RBP	Gı	oup
%	bps v PY	%	bps v PY	%	bps v PY
56.7%	+90bps	91.5%	+20bps	59.3%	+60bps
14.1%	-30bps	2.8%	-130bps	13.2%	-30bps
20.8%	+40bps	53.2%	-380bps	23.2%	-10bps
	% 56.7%	56.7% +90bps 14.1% -30bps	% bps v PY % 56.7% +90bps 91.5% 14.1% -30bps 2.8%	% bps v PY % bps v PY 56.7% +90bps 91.5% +20bps 14.1% -30bps 2.8% -130bps	% bps v PY % bps v PY % 56.7% +90bps 91.5% +20bps 59.3% 14.1% -30bps 2.8% -130bps 13.2%

Profitability by business segment



	H	11		
	2014	2013		
	%	%		
ENA	22.7%	21.4%		
LAPAC	17.7%	18.2%		
RUMEA	18.7%	20.1%		
FOOD	22.4%	22.5%		
Group excluding RBP	20.8%	20.4%		
RBP	53.2%	57.0%		
Group	23.2%	23.3%		

Adjusted to exclude the impact of exceptional items

Net Working Capital



		NWC	
	HY14	HY13	FY13
	£m	£m	£m
Inventory	748	785	746
% to last 12 month revenue	8%	8%	7%
Receivables	1,371	1,466	1,306
% to last 12 month revenue	14%	15%	13%
Payables	(2,992)	(3,106)	(2,915)
% to last 12 month revenue	-31%	-31%	-29%
Net working capital	(873)	(855)	(863)
% to last 12 month revenue	-9%	-9%	-9%

Free cash flow HY 2014



	H1		
	2014	2013	
	£m	£m	
Adjusted Operating Profit*	1,081	1,163	
Share based payment	27	29	
Depreciation and amortisation	87	80	
Net Capital expenditure	(80)	(85)	
Movement in net working capital	(2)	126	
Movement in provisions and other creditors	(90)	(54)	
Other non-cash movements in operating profit**	(8)	1	
Trading cashflow	1,015	1,260	
Exceptional costs	(47)	(24)	
Operating Cashflow	968	1,236	
Net interest paid	(14)	(13)	
Taxation paid	(225)	(330)	
Free Cashflow	729	893	
Free Cashflow as % of Net Income	90%	135%	
Closing net debt	(2,237)	(2,760)	

^{*}Adjusted to exclude the impact of exceptional items

^{**}Includes gains/losses on sale of businesses, PPE and intangible assets, and fair value movements



Rakesh Kapoor Chief Executive Officer



New initiatives for H2 2014





Initiatives for H2 2014 - Health

Airborne[®] Everyday Gummies









Airborne® Everyday Gummies
Real immune support PLUS Multi-vitamins

Initiatives for H2 2014 - Health

Airborne® Dual Action











Airborne® Dual Action

Clinically Proven to Boost immune system – Beta Immune Booster plus Anti-oxidants to keep immune system healthy

Initiatives for H2 2014 – Health Mucinex® Fast-Max Hot Drinks





Mucinex® Fast-Max Hot Drinks

Combine max. strength ingredients with mucus-busting power of Mucinex. Works fast and pleasant honey-lemon has a soothing and comforting effect!

Initiatives in H2 2014 - Health

Scholl® Velvet Smooth further rollout













Scholl® Velvet Smooth

Perfectly smooth skin in one application

Initiatives in H2 2014 – Health Velvet Smooth Pedi – US & Brazil







Initiatives in H2 2014 - Health

Amope[®] Pedi Perfect







Amope® Pedi Perfect

Provide a professional foot grooming experience at home – Perfectly smooth skin in one application

Initiatives for H2 2014 – Health Durex® Devices









Durex® Devices

A complete range of pleasure toys designed specially for the female body - allows lovers to experience the transformational power of great sex





Initiatives for H2 2014 – Hygiene Veet® Infini'Silk





Permanent Hair Reduction: Harnessing the same technology found in clinics and salons - in the comfort of your own home

Initiatives for H2 2014 – Hygiene Finish® All-in-1 Concentrated Gels Range





Finish® All-In-One Concentrated Gels Range

Amazing results even on short cycles

Initiatives for H2 2014 – Hygiene

Harpic® Power Plus Rapid Action





Harpic® Power Plus Rapid Action

First toilet bowl cleaner with a "1 minute" action - gives that sparkling clean toilet you expect from Harpic

Initiatives for H2 2014 – Hygiene Sagrotan® Power & Pur Tipp Topp cleaner













Sagrotan® Power & Pur Tipp Topp cleaner

Designed to stay at your fingertips so every touch-up is a healthy one

Initiatives for H2 2014 – Hygiene Dettol® Lasting Fresh









Dettol® Lasting Fresh

Combining Dettol's trusted protection and unique Lasting Fresh Technology, for a feeling of freshness and health that lasts longer

Initiatives for H2 2014 – Hygiene Mortein® Outdoor









Mortein® Outdoor

Reclaiming the outdoors from insects with natural protection of citronella essential oil





Initiatives for H2 2014 – Home



Vanish® Gold



New premium gold standard in stain removal – Removes stains in 30 seconds

Initiatives for H2 2014 – Home Air Wick®





Air Wick® Premium Aerosol

Airwick's 1st premium aerosol range in France. Superior Fragrance Experience (water free formula)


Initiatives for H2 2014 - Home

Air Wick® Eternal Scents









Air Wick® Eternal Scents

Associates the benefit of a candle with Essential oil-infused gel for continuous fragrance (even when not lit)

Initiatives – Health Durex® #turnofftoturnon



- >2 bn Campaign Impressions
- >85 mn Video Views (All Platforms)
- >347 mn engagement
- >56 countries, in 23 Languages







We introduced a new artist to the world, and even released a single





Full Year Targets

2014: Targets



Net revenue

+4-5%

Operating margin

Flat- moderate expansion**

*at constant rates (ex RBP) including the immaterial residual impact of the BMS collaboration. ** ex-RBP, and adjusted to exclude the impact of exceptional items.

2014: Targets



Net revenue +4-5%

Operating margin
Continued expansion in H2**

*at constant rates (ex RBP) including acquisitions and disposals . ** ex-RBP, and adjusted to exclude the impact of exceptional items.



Appendices

Analysis of Exceptional costs



	Total	2014 Total P&L		Total cash	
	Guidance	HY	to date	to date	
	£m	£m	£m	£m	
Acquisition, integration and restructuring	170	21	149	130	
KY acquisition and integration costs	20	1	1	1	
Litigation provisions	225	-	225	36	

Reconciliation of Operating Profit to Adjusted Operating Profit



	2014	2013	2012*	2011
	HY	FY	FY	FY
	£m	£m	£m	£m
Operating profit	1,059	2,345	2,442	2,395
Adjusting items:				
Acquisition, integration and restructuring	22	46	135	92
Litigation provisions	-	225	-	-
Adjusted operating profit	1,081	2,616	2,577	2,487

^{*2012} numbers have been restated to reflect the amendment of IAS 19 and the presentation to net interest. 2011 has not been restated.

Revenue growth by Business segment Q2 2014



	LFL	Acq	FX	Reported
	%	%	%	%
ENA	2%	1%	-6%	-4%
LAPAC	6%	1%	-17%	-10%
RUMEA	7%	0%	-17%	-11%
FOOD	2%	0%	-7%	-5%
Group excluding RBP	4%	1%	-11%	-7%
RBP	-5%	0%	-8%	-13%
Group	3%	1%	-11%	-7%

Due to rounding this table will not always cast

Revenue growth by Business segment HY 2014



	LFL	Acq	FX	Reported
	%	%	%	%
ENA	2%	0%	-5%	-3%
LAPAC	7%	3%	-18%	-8%
RUMEA	5%	0%	-17%	-12%
FOOD	3%	0%	-8%	-5%
Group excluding RBP	4%	1%	-10%	-6%
RBP	-8%	0%	-6%	-14%
Group	3%	1%	-10%	-7%

Due to rounding this table will not always cast





	H1 2014	FY 2013
Revenue	£m 37	£m 76
Operating Profit	4	2
Operating Profit %	10.8%	2.6%